Abstract
Mycophenolate mofetil, an immunosuppressant approved for the prevention of transplant rejection, has been used in patients with lupus nephritis. Lertdumrongluk et al. suggest that mycophenolic acid exposure may predict therapeutic responses in severe lupus nephritis, and their initial results confirm that hypothesis. However, it seems that enteric-coated mycophenolate sodium should not be administered to patients provided with therapeutic drug monitoring.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
